Last week, DS Healthcare Group filed its second patent (first one was filed in October 2013) related to a new proprietary topical hair loss treatment. From the news release regarding this development:
“This new patent addresses the composition and methods of a new compound described as a calcium-activated potassium channel opening agent for topical treatment of hair loss.”
According to the company’s CEO Daniel Khesin, this patent-pending molecule will produce better hair regrowth results than topical minoxidil.
The company’s 1 year stock price movement chart: